Dual PI3Kδγ inhibition demonstrates potent anticancer effects in diffuse large B-cell lymphoma models: Discovery and preclinical characterization of LL-00084282

Article

作者: Bhonde, Mandar ; Naik, Aditya ; Goel, Rajan N ; Pawar, Shashikant ; Verma, Mahip K ; Mahajan, Nilesh ; Samant, Charudatt ; Shukla, Manojkumar R ; Nigade, Prashant B ; Mehta, Maneesh ; Bokare, Anand M ; Palle, Venkata P ; Patil, Vinod B ; Modi, Dipak ; Shingare, Manisha ; Koul, Sarita ; Ahirrao, Prajakta ; Marisetti, Ajitkumar ; Dinchhana, Lal ; Reddy, Madhusudhan ; Kuldharan, Sandip ; Kamboj, Rajender Kumar ; Jana, Nirmal ; Akarte, Atul ; Sunkara, Brahmam ; Gundu, Jayasagar ; Kale, Ramesh ; Mahangare, Sachin Jaysing ; Vidhate, Prashant ; Patra, Sukanya ; Gholve, Milind K

Phosphoinositide 3-kinase (PI3K) pathway mediates key signaling events downstream to B-cell receptor (BCR) for survival of mature B-cells, and overexpression or overactivation of PI3Kδ is crucial for B-cell malignancies such as diffuse large B-cell lymphoma (DLBCL). Small molecule PI3Kδγ inhibitors, with a known potential to reduce activated B-cell (ABC)-DLBCL transformation, form an important class of therapeutics approved for follicular lymphoma (FL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL). In this study, we describe discovery of a potent, selective and efficacious dual PI3Kδγ inhibitor, LL-00084282, having a differentiated efficacy profile in human ABC- and germinal center B-cell (GCB)-DLBCL cell lines. LL-00084282 displayed high potency and superior PI3Kδγ engagement with excellent selectivity over other PI3K isoforms at both IC_50/90 concentrations in biochemical and cell-based assays. In contrast to selective PI3Kδ inhibitors, LL-00084282 showed superior and potent anticancer activity in both ABC- and GCB-DLBCL cell lines. LL-00084282 demonstrated in-vivo efficacy in OCI-Ly10 and SU-DHL-6 xenografts with good tolerability. Furthermore, LL-00084282 inhibited pro-inflammatory cytokine secretion and reduced basophil activation in human PBMCs, showing potential implications in immunoinflammatory conditions. Good pharmacokinetic properties in higher species and desirable efficacy profile highlights potential of this novel PI3Kδγ inhibitor for further clinical evaluation in DLBCL patients.

2020-12-10·Journal of medicinal chemistry1区 · 医学

Discovery of a Potent and Selective PI3Kδ Inhibitor (S)-2,4-Diamino-6-((1-(7-fluoro-1-(4-fluorophenyl)-4-oxo-3-phenyl-4H-quinolizin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile with Improved Pharmacokinetic Profile and Superior Efficacy in Hematological Cancer Models

1区 · 医学

Article

作者: Tarage, Anand ; Sayyed, Majid ; Pawar, Shashikant ; Bokare, Anand ; Vidhate, Prashant ; Goel, Rajan ; Reddy, Madhusudhan ; Sunkara, Brahmam ; Mahajan, Nilesh ; Sadasivam, Gayathri ; Verma, Mahip ; Dinchhana, Lal ; Nigade, Prashant ; Tota, Swati ; Samant, Charudatt ; Kulkarni, Sanjeev ; Kanhere, Rupesh ; Gundu, Jayasagar ; Shukla, Manojkumar R. ; Sharma, Sharad ; Sabde, Sudeep ; Ahirrao, Prajakta ; Pachpute, Vipul ; Palle, Venkata P. ; Jana, Nirmal ; Bhonde, Mandar ; Marisetti, Ajit Kumar ; Dandekar, Manoj ; Kulkarni, Chaitanya ; Mehta, Maneesh ; Chaudhari, Vinod D. ; Shingare, Manisha ; Volam, Harish ; Reddy, Neetinkumar ; Phukan, Samiron ; Koul, Sarita ; Lagad, Dipak ; Akarte, Atul ; Goyal, Hemant ; Trivedi, Sneha ; Mahangare, Sachin J. ; Patil, Vinod ; Bhagwat, Shankar ; Naik, Aditya ; Cheemala, Murthy ; Bernstein, Peter R. ; Modi, Dipak ; Phadtare, Ramesh ; Singh, Minakshi ; Kamboj, Rajender Kumar ; Narasimham, Lakshmi ; Gole, Gopal ; Gholve, Milind ; Tamane, Kaustubh ; Patra, Sukanya ; Mallurwar, Sadanand

PI3Kδ inhibitors have been approved for B-cell malignancies like CLL, small lymphocytic lymphoma, and so forth. However, currently available PI3Kδ inhibitors are nonoptimal, showing weakness against at least one of the several important properties: potency, isoform selectivity, and/or pharmacokinetic profile. To come up with a PI3Kδ inhibitor that overcomes all these deficiencies, a pharmacophoric expansion strategy was employed. Herein, we describe a systematic transformation of a "three-blade propeller" shaped lead, 2,3-disubstituted quinolizinone 11, through a 1,2-disubstituted quinolizinone 20 to a novel "four-blade propeller" shaped 1,2,3-trisubstituted quinolizinone 34. Compound 34 has excellent potency, isoform selectivity, metabolic stability across species, and exhibited a favorable pharmacokinetic profile. Compound 34 also demonstrated a differentiated efficacy profile in human germinal center B and activated B cell-DLBCL cell lines and xenograft models. Compound 34 qualifies for further evaluation as a candidate for monotherapy or in combination with other targeted agents in DLBCLs and other forms of iNHL.

100 项与 LL-00084282 相关的药物交易

登录后查看更多信息